Verona Pharma plc VRNA
$ 38.9
11.2%
Quarterly report 2024-Q3
added 11-04-2024
Verona Pharma plc Balance Sheet 2011-2024 | VRNA
Annual Balance Sheet Verona Pharma plc
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-222 M | -217 M | -143 M | -188 M | -22 M | -19.8 M | -31.4 M | -49.1 M | -5.22 M | -15.5 M | -996 K | -1.55 M | -3.92 M |
Long Term Debt |
48.4 M | 9.77 M | 4.87 M | - | 491 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.18 M | 675 K | 648 K | 798 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
50.1 M | 9.97 M | 5.16 M | 5.15 M | 1.65 M | 1.1 M | 1.03 M | 990 K | - | - | - | - | - |
Total Current Liabilities |
8.69 M | 19 M | 33.4 M | 14.2 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
58.8 M | 29 M | 38.6 M | 19.4 M | 45.1 M | 74.3 M | 89.5 M | 14.4 M | 2.69 M | 816 K | 807 K | 322 K | 242 K |
Deferred Revenue |
- | - | - | - | 60 K | 106 K | 152 K | - | - | - | - | - | - |
Retained Earnings |
-388 M | -333 M | -264 M | - | - | - | - | -35.4 M | -34.2 M | -24.5 M | -21.7 M | -17.2 M | -12.7 M |
Total Assets |
308 M | 259 M | 187 M | 204 M | 45.1 M | 74.3 M | 89.5 M | 56.9 M | 11 M | 20.4 M | 4.22 M | 4.53 M | 6.53 M |
Cash and Cash Equivalents |
272 M | 228 M | 148 M | 188 M | 30.4 M | - | - | - | - | - | - | - | - |
Book Value |
249 M | 230 M | 148 M | 185 M | - | - | - | 42.5 M | 8.28 M | 19.6 M | 3.41 M | 4.21 M | 6.29 M |
Total Shareholders Equity |
249 M | 230 M | 148 M | 185 M | 42.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Verona Pharma plc
2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
120 M | 120 M | 48.4 M | 19.9 M | 19.9 M | 19.8 M | 9.77 M | 5.04 M | 4.98 M | 4.93 M | 4.87 M | 4.82 M | 4.77 M | 4.68 M | 4.64 M | 4.64 M | 4.64 M | 4.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
223 M | 218 M | 50.1 M | 19.9 M | 19.9 M | 19.9 M | 9.97 M | 5.26 M | 5.11 M | 5.1 M | 5.16 M | 5.62 M | 5.74 M | 5.04 M | 5.15 M | 5.15 M | 5.15 M | 5.15 M | 652 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
251 M | 266 M | 58.8 M | 28.9 M | 30.8 M | 46.4 M | 29 M | 37.4 M | 44 M | 43 M | 38.6 M | 33.4 M | 64.1 M | 17.7 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 13.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
169 K | 21.3 M | - | - | - | - | - | - | - | - | - | - | 40.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-528 M | -485 M | -388 M | -374 M | -359 M | -350 M | -333 M | -322 M | -307 M | -289 M | -264 M | -240 M | -251 M | -228 M | -207 M | -207 M | -207 M | -207 M | -142 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
382 M | 434 M | 308 M | 292 M | 304 M | 323 M | 259 M | 275 M | 155 M | 169 M | 187 M | 202 M | 219 M | 190 M | 204 M | 204 M | 204 M | 204 M | 56.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
336 M | 405 M | 272 M | 257 M | 271 M | 291 M | 228 M | 232 M | 112 M | 133 M | 148 M | 167 M | 146 M | 170 M | 188 M | 188 M | 188 M | 188 M | 30.4 M | - | - | - | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
130 M | 168 M | 249 M | 264 M | 273 M | 277 M | 230 M | 237 M | 111 M | 126 M | 148 M | 168 M | 154 M | 172 M | 185 M | 185 M | 185 M | 185 M | 42.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
130 M | 168 M | 249 M | 264 M | 273 M | 277 M | 230 M | 237 M | 111 M | 126 M | 148 M | 168 M | 154 M | 172 M | 185 M | 185 M | 185 M | 185 M | 42.7 M | - | - | - | 78.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency